DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Caisse DE Depot ET Placement DU Quebec

Caisse DE Depot ET Placement DU Quebec increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 235.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 135,323 shares of the medical device company’s stock after buying an additional 94,923 shares during the quarter. Caisse DE Depot ET Placement DU Quebec’s holdings in DexCom were worth $9,072,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. purchased a new position in DexCom during the second quarter worth about $25,000. Sachetta LLC raised its stake in shares of DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after buying an additional 171 shares in the last quarter. Riverview Trust Co grew its holdings in DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after acquiring an additional 232 shares during the period. DT Investment Partners LLC grew its stake in shares of DexCom by 492.2% during the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after purchasing an additional 315 shares during the period. Finally, RPg Family Wealth Advisory LLC purchased a new position in shares of DexCom in the 3rd quarter valued at about $57,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

DXCM has been the topic of a number of research analyst reports. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Sanford C. Bernstein boosted their price target on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Piper Sandler reaffirmed an “overweight” rating and issued a $90.00 price objective on shares of DexCom in a research note on Monday, August 26th. Wells Fargo & Company boosted their target price on DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, October 25th. Finally, Oppenheimer dropped their price target on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Trading Up 1.7 %

Shares of DXCM opened at $79.31 on Tuesday. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The stock has a fifty day moving average of $71.58 and a two-hundred day moving average of $87.18. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The company has a market capitalization of $30.98 billion, a PE ratio of 47.49, a price-to-earnings-growth ratio of 2.38 and a beta of 1.17.

Insider Activity at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. This represents a 0.28 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 5,431 shares of company stock worth $399,319. 0.30% of the stock is currently owned by insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.